New set-up for IT at Bayer

BayerBayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses. The realignment is part of the efficiency and structural measures that Bayer announced back in November 2018.

"We're not only looking to achieve savings but to use this opportunity to establish a new set-up for our IT function. The goal is to deliver new solutions in health and agriculture much faster," says Wolfgang Nickl, Chief Financial Officer and member of the Board of Management at Bayer. "The support of external partners is essential for Bayer - and that's why we have chosen leading providers that we are already working with," adds Daniel Hartert, Chief Information Officer at Bayer. The partners will take on around 950 IT employees (full-time equivalents) from Bayer in Germany. The following strategic partners have been selected:

  • Atos for Global Workplace Services and Security Operations
  • Capgemini for Business Intelligence Analytics and Controlling (BIAC), Enterprise Resource Planning (excluding HR), global IT Infrastructure, Service Integration, and Unified Communications & Collaboration
  • Cognizant for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Crop Science Division
  • Tata Consultancy Services for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Consumer Health and Pharmaceuticals divisions, the corporate functions and HR IT

The six-year contract can be extended by one year. The respective employees in Germany will be moving to the partners in the coming months. "Parting ways with so many employees is not easy. However, this change also comes with opportunities. We are convinced that our IT colleagues will have good development prospects with the specialized providers. The respective activities will not be continued at Bayer," says Hartert.

Internally, the Bayer IT function will be organized in agile teams that are closely linked to the businesses. The aim is to digitalize the whole value chain: from research and development to product supply, marketing and sales.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...